ID: ALA341692

Max Phase: Preclinical

Molecular Formula: C38H50F2N2O3

Molecular Weight: 620.83

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCC(=O)OC(CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1

Standard InChI:  InChI=1S/C38H50F2N2O3/c1-2-3-4-5-6-7-11-14-37(43)45-36(31-12-9-8-10-13-31)23-24-41-25-27-42(28-26-41)29-30-44-38(32-15-19-34(39)20-16-32)33-17-21-35(40)22-18-33/h8-10,12-13,15-22,36,38H,2-7,11,14,23-30H2,1H3

Standard InChI Key:  IXQPQADYPIEKQC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 620.83

Molecular Weight (Monoisotopic): 620.3789

AlogP: 8.50

#Rotatable Bonds: 19

Polar Surface Area: 42.01

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.93

CX LogP: 9.19

CX LogD: 8.55

Aromatic Rings: 3

Heavy Atoms: 45

QED Weighted: 0.10

Np Likeness Score: -0.41

References

1. Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC, Rothman RB..  (1996)  Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909.,  39  (24): [PMID:8941381] [10.1021/jm960551t]

2. Lewis DB, Matecka D, Zhang Y, Hsin LW, Dersch CM, Stafford D, Glowa JR, Rothman RB, Rice KC..  (1999)  Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents.,  42  (24): [PMID:10585212] [10.1021/jm990291q]

Source

Source(1):

• Scientific Literature